SELLAS Life Sciences Group, Inc.
NASDAQ: SLS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Angelos Stergiou
- Employees
- 13
- Headquarters
- New York, United States
- IPO year
- 2008
- Market cap
- $1.3B
- Website
- https://sellaslifesciences.com
Loading SLS…
Loading profile data…Frequently asked questions about SLS
What does SELLAS Life Sciences Group, Inc. (SLS) do?
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a sel...
Where does SLS trade?
SELLAS Life Sciences Group, Inc. (SLS) trades on the NASDAQ.
What sector is SLS in?
SELLAS Life Sciences Group, Inc. (SLS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of SELLAS Life Sciences Group, Inc.?
Angelos Stergiou is the chief executive officer of SELLAS Life Sciences Group, Inc. (SLS).
Where is SELLAS Life Sciences Group, Inc. headquartered?
SELLAS Life Sciences Group, Inc. is headquartered in United States.
Does SLS pay a dividend?
SELLAS Life Sciences Group, Inc. (SLS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLS go public?
SELLAS Life Sciences Group, Inc. (SLS) completed its initial public offering in 2008.